Health Care • Biotechnology: Pharmaceutical Preparations
$1.22 ▲ +0.03
(+2.52%)
MKT CAP: $5.9M • VOL: 15.8K
52W L $1 52W H $3
ROARABLE / RQD
D • 47/100
PIOTROSKI
1 / 9
ALZN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-30 | FY 2024
FILED 2025-04-30 | FY 2023
FILED 2024-04-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.8M | -$4.5M | -$9.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$8.8M | -$4.5M | -$9.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.1M | -$6.6M | -$8.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$8.1M | -$6.6M | -$8.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $2.7M | $3.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.2M | $3.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALZN.